Abstract
Nitrofurantoin lung toxicity was diagnosed among ten patients receiving 50 mg/day to prevent recurrent urinary tract infection. In six patients a symptomatic period of 3-36 months preceded the diagnosis. All but one patient, with irreversible lung injury at presentation recovered completely, five after drug discontinuation and four after steroids therapy. Large amount of data regarding unexpected, sometimes severe pulmonary toxicity during nitrofurantoin therapy should maintain a high index of suspicion for the drug usage among patients with non-resolving pulmonary symptoms. Alternatively, the use of other antimicrobial agents with a better risk-to-benefit ratio should be considered.
Keywords: Lung, nitrofurantoin, toxicity
Current Drug Safety
Title: Nitrofurantoin Pulmonary Toxicity: Neglected Threat
Volume: 5 Issue: 2
Author(s): Emilia Hardak, Gidon Berger, Norberto Krivoy, Anna Solomonov and Mordechai Yigla
Affiliation:
Keywords: Lung, nitrofurantoin, toxicity
Abstract: Nitrofurantoin lung toxicity was diagnosed among ten patients receiving 50 mg/day to prevent recurrent urinary tract infection. In six patients a symptomatic period of 3-36 months preceded the diagnosis. All but one patient, with irreversible lung injury at presentation recovered completely, five after drug discontinuation and four after steroids therapy. Large amount of data regarding unexpected, sometimes severe pulmonary toxicity during nitrofurantoin therapy should maintain a high index of suspicion for the drug usage among patients with non-resolving pulmonary symptoms. Alternatively, the use of other antimicrobial agents with a better risk-to-benefit ratio should be considered.
Export Options
About this article
Cite this article as:
Hardak Emilia, Berger Gidon, Krivoy Norberto, Solomonov Anna and Yigla Mordechai, Nitrofurantoin Pulmonary Toxicity: Neglected Threat, Current Drug Safety 2010; 5 (2) . https://dx.doi.org/10.2174/157488610790936169
DOI https://dx.doi.org/10.2174/157488610790936169 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resveratrol: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Herpetic (Non-Cytomegalovirus) Retinal Infections in Patients with the Acquired Immunodeficiency Syndrome
Current HIV Research Angiogenesis in Chronic Lymphocytic Leukemia
Current Angiogenesis (Discontinued) A Review on Natural Products for Controlling Type 2 Diabetes with an Emphasis on their Mechanisms of Actions
Current Diabetes Reviews Impact of Macrophages in Atherosclerosis
Current Medicinal Chemistry Practical Approach to Children Presenting with Eosinophila and Hypereosinophilia
Current Pediatric Reviews Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective
Current Rheumatology Reviews The Role of Cytokines in T Help Responses to Viruses
Current Immunology Reviews (Discontinued) From a Dull Enzyme to Something Else: Facts and Perspectives Regarding Aldose Reductase
Current Medicinal Chemistry Postoperative Care of the Transplanted Patient
Current Cardiology Reviews Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
Current Pharmaceutical Design Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cutaneous Lupus Erythematosus in Children
Current Pediatric Reviews Pleural Involvement in Systemic Disorders
Current Drug Targets - Inflammation & Allergy Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets Biological Agents in Familial Mediterranean Fever Focusing on Colchicine Resistance and Amyloidosis
Current Medicinal Chemistry Autoantibodies as Biomarkers for ANCA-Associated Vasculitides
Current Immunology Reviews (Discontinued)